MQS Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

MQS Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,672	Closed	-$269K	–	422
2024 Q3	$269K	Buy	+3,672	New	+$276K	0.15%	289

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

MQS Management's ITCI Position: Q4 2024 in Review

MQS Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 3,672 shares — an estimated $269K sold.

MQS Management first reported a position in ITCI in Q3 2024 and held it in 1 quarter. The position peaked at $269K in Q3 2024. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

MQS Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
MQS Management sold 3,672 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $269K.
MQS Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 1 quarter.
MQS Management's Intra-Cellular Therapies Inc. position peaked at $269K in Q3 2024.
387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on MQS Management's 13F filing for Q4 2024, filed 7 Feb 2025.